Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Correlation between CRP and early failure of arteriovenous fistula (AVF).

Khavanin Zadeh M, Mohammadipour S, Omrani Z.

Med J Islam Repub Iran. 2015 Jun 8;29:219. eCollection 2015.

2.

Association Between Vascular Access Dysfunction and Subsequent Major Adverse Cardiovascular Events in Patients on Hemodialysis: A Population-Based Nested Case-Control Study.

Kuo TH, Tseng CT, Lin WH, Chao JY, Wang WM, Li CY, Wang MC.

Medicine (Baltimore). 2015 Jul;94(26):e1032. doi: 10.1097/MD.0000000000001032.

3.

Individualizing anaemia therapy.

de Francisco AL.

NDT Plus. 2010 Dec;3(6):519-26. doi: 10.1093/ndtplus/sfq164. Epub 2010 Sep 21.

4.

Chapter 3: Use of ESAs and other agents to treat anemia in CKD.

[No authors listed]

Kidney Int Suppl (2011). 2012 Aug;2(4):299-310. No abstract available.

5.

Association of higher erythropoiesis stimulating agent dose and mortality in children on dialysis.

Lestz RM, Fivush BA, Atkinson MA.

Pediatr Nephrol. 2014 Oct;29(10):2021-8. doi: 10.1007/s00467-014-2820-9. Epub 2014 May 3.

6.

Renal anemia control in Lithuania: influence of local conditions and local guidelines.

Ziginskiene E, Kuzminskis V, Petruliene K, Vaiciuniene R, Stankuviene A, Bumblyte IA.

ScientificWorldJournal. 2013 Dec 3;2013:260915. doi: 10.1155/2013/260915. eCollection 2013.

7.

Role of alpha-lipoic acid in the management of anemia in patients with chronic renal failure undergoing hemodialysis.

El-Nakib GA, Mostafa TM, Abbas TM, El-Shishtawy MM, Mabrouk MM, Sobh MA.

Int J Nephrol Renovasc Dis. 2013 Aug 27;6:161-8. doi: 10.2147/IJNRD.S49066. eCollection 2013.

8.

Influence of safety warnings on ESA prescribing among dialysis patients using an interrupted time series.

Thamer M, Zhang Y, Lai D, Kshirsagar O, Cotter D.

BMC Nephrol. 2013 Aug 9;14:172. doi: 10.1186/1471-2369-14-172.

9.

Hemoglobin targets for chronic kidney disease patients with anemia: a systematic review and meta-analysis.

Jing Z, Wei-jie Y, Nan Z, Yi Z, Ling W.

PLoS One. 2012;7(8):e43655. doi: 10.1371/journal.pone.0043655. Epub 2012 Aug 30. Review.

10.

Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis.

Koulouridis I, Alfayez M, Trikalinos TA, Balk EM, Jaber BL.

Am J Kidney Dis. 2013 Jan;61(1):44-56. doi: 10.1053/j.ajkd.2012.07.014. Epub 2012 Aug 22.

11.

Iron inhibits respiratory burst of peritoneal phagocytes in vitro.

Gotfryd K, Jurek A, Kubit P, Klein A, Turyna B.

ISRN Urol. 2011;2011:605436. doi: 10.5402/2011/605436. Epub 2011 Dec 8.

12.

Naturally occurring higher hemoglobin concentration does not increase mortality among hemodialysis patients.

Goodkin DA, Fuller DS, Robinson BM, Combe C, Fluck R, Mendelssohn D, Akizawa T, Pisoni RL, Port FK.

J Am Soc Nephrol. 2011 Feb;22(2):358-65. doi: 10.1681/ASN.2010020173. Epub 2010 Dec 16.

13.

Use of agents stimulating erythropoiesis in digestive diseases.

Moreno López R, Sicilia Aladrén B, Gomollón García F.

World J Gastroenterol. 2009 Oct 7;15(37):4675-85. Review.

14.

Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple intravenous administrations: an open-label randomised controlled trial.

Sörgel F, Thyroff-Friesinger U, Vetter A, Vens-Cappell B, Kinzig M.

BMC Clin Pharmacol. 2009 May 22;9:10. doi: 10.1186/1472-6904-9-10.

15.

Erythropoietin therapy, hemoglobin targets, and quality of life in healthy hemodialysis patients: a randomized trial.

Foley RN, Curtis BM, Parfrey PS.

Clin J Am Soc Nephrol. 2009 Apr;4(4):726-33. doi: 10.2215/CJN.04950908. Epub 2009 Apr 1.

16.

Safety issues with intravenous iron products in the management of anemia in chronic kidney disease.

Hayat A.

Clin Med Res. 2008 Dec;6(3-4):93-102. doi: 10.3121/cmr.2008.811. Review.

17.

Chronic kidney disease, heart failure and anemia.

Virani SA, Khosla A, Levin A.

Can J Cardiol. 2008 Jul;24 Suppl B:22B-4B. Review.

18.

Recombinant human epoetin beta in the treatment of renal anemia.

Locatelli F, Pozzoni P, Vecchio LD.

Ther Clin Risk Manag. 2007 Jun;3(3):433-9.

19.

Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review.

Little JA, McGowan VR, Kato GJ, Partovi KS, Feld JJ, Maric I, Martyr S, Taylor JG 6th, Machado RF, Heller T, Castro O, Gladwin MT.

Haematologica. 2006 Aug;91(8):1076-83.

20.

Iron sucrose augments homocysteine-induced endothelial dysfunction in normal subjects.

Zheng H, Huang X, Zhang Q, Katz SD.

Kidney Int. 2006 Feb;69(4):679-84.

Supplemental Content

Support Center